6934
HCmed Innovations Co., Ltd. designs, develops, manufactures, and sells mesh nebulizers to deliver liquid medications into the respiratory airways in the United States, Europe and Asia. The company's products include Pulmogine, a vibrating mesh nebulizer to nebulize a range of liquid medications to treat respiratory diseases and their symptoms in children and adults; and AdheResp, a breath-actuate… Read more
6934 (6934) - Net Assets
Latest net assets as of September 2025: NT$266.79 Million TWD
Based on the latest financial reports, 6934 (6934) has net assets worth NT$266.79 Million TWD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$354.66 Million) and total liabilities (NT$87.87 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$266.79 Million |
| % of Total Assets | 75.22% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 38.75 |
6934 - Net Assets Trend (2020–2024)
This chart illustrates how 6934's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for 6934 (2020–2024)
The table below shows the annual net assets of 6934 from 2020 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | NT$209.31 Million | -24.44% |
| 2023-12-31 | NT$277.01 Million | +53.07% |
| 2022-12-31 | NT$180.97 Million | +205.02% |
| 2021-12-31 | NT$-172.32 Million | -18.21% |
| 2020-12-31 | NT$-145.78 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to 6934's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 21122900000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | NT$300.34 Million | 143.49% |
| Other Comprehensive Income | NT$12.14 Million | 5.80% |
| Other Components | NT$434.84 Million | 207.75% |
| Total Equity | NT$209.31 Million | 100.00% |
6934 Competitors by Market Cap
The table below lists competitors of 6934 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Thai Nguyen International Hospital JSC
VN:TNH
|
$48.35 Million |
|
Cinclus Pharma
ST:CINPHA
|
$48.37 Million |
|
SysJust Co., Ltd.
TWO:3158
|
$48.37 Million |
|
ImageneBio, Inc.
NASDAQ:IMA
|
$48.40 Million |
|
Wir Asia Tbk PT
JK:WIRG
|
$48.34 Million |
|
Cinclus Pharma Holding AB (publ)
F:J8P
|
$48.34 Million |
|
Bluebird bio Inc
NASDAQ:BLUE
|
$48.34 Million |
|
Wallbridge Mining Company Limited
OTCQB:WLBMF
|
$48.32 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in 6934's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 277,011,000 to 209,313,000, a change of -67,698,000 (-24.4%).
- Net loss of 78,213,000 reduced equity.
- New share issuances of 230,000 increased equity.
- Other comprehensive income increased equity by 12,318,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | NT$-78.21 Million | -37.37% |
| Share Issuances | NT$230.00K | +0.11% |
| Other Comprehensive Income | NT$12.32 Million | +5.88% |
| Other Changes | NT$-2.03 Million | -0.97% |
| Total Change | NT$- | -24.44% |
Book Value vs Market Value Analysis
This analysis compares 6934's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 11.83x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-12-31 | NT$-5.94 | NT$82.00 | x |
| 2021-12-31 | NT$-9.82 | NT$82.00 | x |
| 2022-12-31 | NT$8.38 | NT$82.00 | x |
| 2023-12-31 | NT$10.37 | NT$82.00 | x |
| 2024-12-31 | NT$6.93 | NT$82.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently 6934 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -37.37%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -55.23%
- • Asset Turnover: 0.57x
- • Equity Multiplier: 1.18x
- Recent ROE (-37.37%) is below the historical average (-35.34%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2020 | 0.00% | -190.45% | 0.27x | 0.00x | NT$-46.98 Million |
| 2021 | 0.00% | -74.34% | 0.61x | 0.00x | NT$-22.95 Million |
| 2022 | -79.46% | -2219.67% | 0.03x | 1.14x | NT$-161.89 Million |
| 2023 | -59.90% | -1796.71% | 0.03x | 1.18x | NT$-193.63 Million |
| 2024 | -37.37% | -55.23% | 0.57x | 1.18x | NT$-99.14 Million |
Industry Comparison
This section compares 6934's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $1,188,209,400
- Average return on equity (ROE) among peers: 10.09%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| 6934 (6934) | NT$266.79 Million | 0.00% | 0.33x | $48.34 Million |
| Health & Life Co., Ltd. (1781) | $393.05 Million | 6.17% | 1.08x | $12.92 Million |
| Hi-Clearance (1788) | $3.00 Billion | 11.98% | 0.65x | $104.25 Million |
| Radiant Innovation (3373) | $865.89 Million | -3.30% | 0.08x | $18.76 Million |
| Wellell Inc (4106) | $458.47 Million | 22.17% | 0.32x | $37.12 Million |
| Rossmax International Ltd (4121) | $1.66 Billion | 8.16% | 1.02x | $34.41 Million |
| United Orthopedic (4129) | $2.22 Billion | 5.87% | 0.94x | $279.97 Million |
| Dynamic Medical Technologies (4138) | $1.70 Billion | 12.34% | 0.81x | $39.16 Million |
| Ok Biotech Co Ltd (4155) | $452.10 Million | 21.38% | 0.72x | $44.61 Million |
| Bioptik Technology (4161) | $824.15 Million | 10.40% | 0.82x | $30.48 Million |
| EPS Bio Technology Corp. (4183) | $304.55 Million | 5.68% | 0.78x | $4.27 Million |